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ABSTRACT
Objective: The goal of this study was to develop and characterize an ion-activated in situ gel-forming brimonidine tartrate, solution eye drops 
containing xanthan gum as a mucoadhesive polymer.
Method: Sol-gel formulation was prepared using gellan gum as an ion-activated gel-forming polymer, xanthan gum as mucoadhesive agent, and 
hydroxypropyl methyl cellulose (HPMC E50LV) as release retardant polymer. Phenylethyl alcohol is used as preservatives in borate buffer. The 23 
factorial design was employed to optimize the formulation considering the concentration of gelrite, xanthan gum and HPMC as independent variables, 
gelation time, gel strength, and mucoadhesive force (N). Gelation time , gel strength, mucoadhesive force (N), viscosity (cP) and in vitro percentage 
drug release were chosen as dependent variables. The formulation was characteristics for pH, clarity, isotonicity, sterility, rheological behavior, and in 
vitro drug release, ocular irritation, and ocular visualization.
Result: Based on desirability index of responses, the formulation containing a concentration of gelrite (0.4%), xanthan gum (0.21%), and HPMC 
(HPMC E50 (0.24%) was found to be the optimized formulation concentration developed by 23 factorial design. The solution eye drops resulted in 
an in situ phase change to gel-state when mixed with simulated tear fluid. The gel formation was also confirmed by viscoelastic measurements. Drug 
release from the gel followed non-fickian mechanism with 88% of drug released in 10 h, thus increased the residence time of the drug.
Conclusion: An in situ gelling system is a valuable alternative to the conventional system with added benefits of sustained drug release which may 
ultimately result in improved patient compliance.
Keywords: Xanthan gum, Hen’s egg test-chorioallantoic membrane test, Brimonidine tartrate.
INTRODUCTION
Drug activity is a result of the molecular interaction(s) in certain 
cells; it is, therefore, easily deduced that it is necessary for the drug 
to reach the site of action following administration at sufficient 
concentrations. The conventional drug delivery such as suspension, 
ointment, and solution shows drawbacks such as binding with the 
lachrymal proteins, drainage of the instilled solutions, lachrimation 
and tear turnover, limited corneal area, and poor corneal metabolism, 
and non-productive absorption. For the therapeutic treatment of most 
ocular problems, the topical administration seems to be the preferred 
route. However, the conventional ophthalmic solutions exhibit poor 
bioavailability and therapeutic response due to the rapid pre-corneal 
elimination of the drug. This is challenged by proper designing of in situ 
gel systems, which are instilled as drops into the eye and undergo a sol-
gel transition in the cul-de-sac [1-3]. A further approach to optimize 
the ocular dosage form is the incorporation of the mucoadhesive 
polymers. Interactions of suitable natural and synthetic polymers 
with the mucus layer of eye tissues increase the precorneal residence 
time of the preparation. The intimate contact may result in high drug 
concentration in the local area and hence high drug flux through the 
absorbing tissue [4-6].
The aim of this work is to formulate ocular in situ gelling systems using 
ion activated polymer containing Brimonidine tartrate (BT) and to 
evaluate the performance of the prepared in situ gelling system.
METHODS
The following materials are used for the study; BT (FDC Limited 
Mumbai), Gelrite (Applied Biosciences [KELCO], Mumbai), Xanthan 
gum (Kajoba Gums, Mumbai), Hydroxypropyl methyl cellulose (HPMC) 
E50 LV (LOBA chemicals, Mumbai), and Rhodamine B (Amrithal 
Chemuax Pvt Ltd., Mumbai). All other chemicals were of analytical 
grade.
Animals
With the approval of Institute Animal Ethical Committee (IAEC/
ABMRCP/PR/2012-2013/19), the study was performed, and the 
protocol was approved as per the CPCSEA guidelines. Albino rabbits 
(Newzeland white rabbit) were used as test species. The right eye was 
designated as control and left one as test eye. In the lower conjunctival 
cul-de-sac, two drops of the formulation were instilled, and for few 
seconds after installation, eyelids were held together, and later normal 
blinking was allowed.
Analytical methods
Scanning for drug absorption (λMax) using double beam spectrophotometer
BT was scanned in 7.4 pH phosphate buffer (10 µmg/ml) using 
double beam ultraviolet (UV)-visible spectrophotometer (UV-1700 
Pharma Spec/Shimadzu Japan) in a wavelength range of 200–
400 nm.
Development of UV spectrophotometric method for analysis of BT
A final concentration of 3, 6, 9, 12, 15, 18, and 21 µg/ml was prepared 
using 7.4 pH phosphate buffer. The absorbance of each concentration 
was measured at 248 nm using UV spectrophotometer against blank. 
The standard curve was obtained by plotting absorbance versus 
concentration in µg/ml.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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In vitro gelation behavior studies of polymers with simulated tear 
fluid (STF)
Concentrations of gelrite, xanthan gum alone and in combinations ranging 
from 0.1 to 1% were prepared and evaluated for in vitro gelling studies. 
The gelling time of formulations of different batches was determined 
by placing 1 or 2 drops of polymeric solution in a vial containing 2ml of 
freshly prepared STF (7.4 pH) equilibrated at 37°C. The gel formation 
was visually observed and time for gelation was noted [7].
Procedure for preparation of in situ gels
Added required quantity of gelrite polymer to the borate buffer 
solution and heated to about 70°C until it is completely dissolved. 
To prepared gelrite solution required quantity of xanthan gum was 
added and stirred well on a magnetic stirrer with slight heating. To 
the above-prepared gelrite/mucoadhesive solution, required quantity 
of drug (0.2% Brimonidine) for their respective batches was added 
with continuous stirring until it is thoroughly mixed. HPMC E50 LV and 
phenylethyl alcohol were added and stirred on a magnetic stirrer. pH 
was checked and  adjusted with buffer. The prepared in situ gel was 
filled in glass vials and closed with closures, capped with aluminum 
caps and sterilized by autoclaving.
Design of experiments employing factorial design
Various batches of formulations were prepared by employing 23 factorial 
designs. The independent variables chosen were concentrations of 
gelrite, HPMC E50 LV, and xanthan gum. The independent variables 
levels were gelrite (0.2, 0.4), xanthan gum (0.2, 0.4), and HPMC E50 LV 
(0.2, 0.4). Levels were assigned after carrying out different trial studies 
on concentration ranging from 0.1 to 1% for the responses. Gelation 
time, gel strength, and mucoadhesive force viscosity in centipoise 
(cP), and in vitro percentage drug release was taken as the response 
parameters and are categorized as dependent variables.
Optimization data analysis and model‑validation
ANOVA was used to establish the statistical validation of the polynomial 
equations generated by Design Expert® software (version 8.0, Stat-Ease 
Inc., Minneapolis, MN). Fitting a multiple linear regression model to a 
23 factorial design gave a predictor equation which was a first-order 
polynomial, having the form:
Y = bo+b1X1+b2X2+b3X3+b12X1X2+b13X1X3+b23X2X3+b123X1X2X3
Where Y is the measured response associated with each factor level 
combination; b0 is an intercept representing the arithmetic average 
of all quantitative outcomes of eight runs; b1 to b123 are regression 
coefficients computed from the observed experimental values of Y. X1, 
X2, and X3 are the coded levels of independent variables. The terms X1 X2, 
X2 X3, and X1 X3 represent the interaction terms.
Fourier transform infrared (FTIR) study [8]
BT and the physical mixture containing pure drug and polymers were 
scanned (8400S/Shimadzu Japan) in the wavenumber region of 400–
4000/cm using KBr pellet method [8].
Measurement of gel strength
A 50 g of prepared gel (25 formulations:7 STF maintained at 37°C 
ratio) was placed in a 100 ml graduated cylinder. A probe was placed 
on the gel, and a weight of 15 g was placed on the probe. The probe was 
allowed to penetrate a fixed distance of 5 cm (30 ml) and the time it 
tooks to travel the distance was recorded [9].
Mucoadhesive strength by modified balance method
The mucoadhesive strength was measured using a modified two-arm 
balance. The biological membrane was fixed to the inverted bottom 
surface of a 100 ml beaker; this was then placed in a larger beaker with 
membrane facing upward. STF (7.4) was added to the larger beaker up 
to the upper surface of the gastric mucosa such that the media remains 
just moistened with the media. Accurately weighted 1gram of the 
preformed gel was put on the inverted beaker and was placed under 
the bottom of stainless steel pan. A preload of 50 g was placed on the 
pan for 5 min to establish adhesion bonding between gel and biological 
membrane. Preload was removed from the pan, and another beaker was 
placed on to another side of the pan. The addition of water was stopped 
when the other side of the pan got detached from the membrane. The 
mass, in grams required to detach the pan from membrane gave the 
measure of mucoadhesive strength [10].
Rheological studies
The viscosity of the instilled ophthalmic solution is an important 
factor in determining residence time of the drug in the eye. Rheological 
behaviors of different ratio of in situ gelling polymeric solutions were 
evaluated on a Brook Field’s DV-I+ model. Based on the viscosity range 
and torque the spindles were selected. The temperature was maintained 
by circulating water at 37°C across the sampler. For gelation, the sample 
solution was mixed with STF in 25 µl:7 µl ratio. The angular viscosity 
was increased gradually from 10 to 100 rpm with an equal wait for 
each rpm. The viscosity measured at both the conditions was plotted 
(angular viscosity versus the angular velocity (rpm) [11].
In vitro release studies
The in vitro drug release was studied using a USP rotating paddle 
apparatus. STF 7.4 maintained at 37°C was used as the medium. The 
paddle speed was set to 50 rpm. 3 ml of the formulation was placed 
in a dialysis tube with cellophane membrane covered cells, and it was 
placed such that it touches the diffusion medium. The drug samples 
were withdrawn at the interval of 1 h for a period of 10 h from 
the medium and were analyzed by UV spectrophotometer at their 
respective wavelength using STF as blank. The cumulative percentage 
drug release and release kinetics were evaluated [12].
PH: The pH of the prepared in situ gelling system was measured using 
pH meter.
Optical clarity studies
Optical clarity of solutions/gels was carried out using UV visible 
spectrophotometer (Shimadzu, 1700 Japan) against STF (7.4) as the 
reference. The formulation was placed in a glass cuvette containing STF, 
care was taken to avoid air bubbles, and the cuvette was inverted up and 
down to confirm gel formation. Transmission of light was measured at 
580 nm, and it was kept constant for all batches [13].
Isotonicity evaluation
Sheep blood was obtained from the slaughterhouse in a container 
containing 4% of Tris-sodium citrate. Few drops of the formulation 
were taken china dish and added few drops of blood and gently shaken 
for mixing blood and formulation. The blood sample was drawn from 
the china dish into red blood cell (RBC) pipette up to 0.5 mark and 
further diluted with RBC diluting fluid. On the hemocytometer, a drop 
of sample was placed and covered with a coverslip on the counting 
chamber. By placing the counting chamber on the mechanical stage of 
the microscope, the cells were observed. The tonicity of the formulation 
was checked under the microscope (45×) for the effect on RBC for 
cremation or swelling and bursting [14].
Test for sterility
According to pharmacopeias, the sterility testing is intended for 
detecting the presence of viable forms of microorganisms in the 
pharmaceutical preparations.
Method of direct transfer
Tests for sterility were performed for fungi, aerobic, and anaerobic bacteria 
using soybean casein digest media and fluid thioglycollate media. According 
to Indian pharmacopoeia for ophthalmic preparation, if the number of 
items in a Batch is not more than 100 containers, the minimum numbers of 
item recommended to be tested are two containers. Two autoclaved glass 
vials each containing 10 ml of the formulation (placebo) were used. This 
study was carried out to obtained sterile preparation, which can be instilled 
into rabbit eyes to understand the ocular behavior and visualization of the 
formulation when it comes in contact with the lachrymal fluid of eye [19].
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Growth promotion (positive control) test
One culture tube containing 10 ml of sterile media was inoculated with 
a sterile loop full of micro-organisms and incubated as per the specified 
conditions. It is labeled as a “positive control.”
Sterility (negative control) test
Uninoculated sterile culture tube containing 10 ml each for fluid 
thioglycollate media and one for soybean casein digest medium were 
taken. These were incubated as per the specified conditions. It is 
labeled as a “negative control.”
Test for aerobic and anaerobic bacteria
Two culture tubes containing 10 ml each of sterile fluid thioglycollate 
media were labeled. 1 ml of the formulation was introduced to the depth 
of culture tube with the help of sterile syringe aseptically and labeled 
as depth D* (for anaerobic). To another culture tube of sterile fluid 
thioglycollate media, 1 ml of the formulation was introduced on to the 
surface of the culture media with the help of sterile syringe aseptically. 
The tube labeled as surface S* (for aerobic). The four tubes (positive, 
negative, and two-labeled test tubes) were incubated at 35°C for 14 days.
Test for fungi
Three sterilized culture tubes containing 10 ml each of sterile soybean-
casein digest media were taken. The tube labeled as a positive control 
was inoculated with a sterile loop full of viable microorganism, Candida 
albicans aseptically. Uninoculated culture tube was labeled as a negative 
control. 1 ml of the formulation was added to the culture tube aseptically 
and labeled as the test. Three tubes were incubated at 25°C for 14 days.
Ocular irritation test (hen’s egg test‑chorioallantoic membrane 
[HET‑CAM] test)
Procedure
In this test, 9th day incubated white leghorn chicken eggs weighing 
between 50 and 60 g were selected. Marked air cell of the egg and placed 
it on the egg cup holder. With the help of a dentist blade, a window 
(2×2 cm) was made on the egg air cell, pared off the outer shell. With 
the forceps, the outer membrane was removed, and care was taken 
to ensure that the CAM was not injured. About 0.3 ml of formulation, 
positive control, and the negative control was applied directly onto the 
CAM surface and left in contact for 5 min. Monitored and recorded the 
time for the appearance of each of the noted endpoints in minutes.
Positive Control
0.3 mL of 0.1N NaOH to provide a baseline for the assay endpoints 
negative control: 0.3 ml of 0.9% NaCl solution to provide a baseline 
for the assay endpoints. Treatment: 0.3 mL of formulation on the CAM 
of the 9th day egg. Observed the reactions on the CAM were observed 
for a period of 300 s (0.5 min, 2 min, and 5 min). Monitored and 
recorded the time for the appearance of each of the noted endpoints, 
in minutes.
End points
Observed endpoints are hemorrhage (bleeding from the vessels), 
vascular lysis (blood vessel disintegration), and coagulation (intra- and 
extra-vascular protein denaturation) on CAM [20,21].
Ocular visualization of in situ gels with fluorophores (rhodamine B)
Two drops of the sterile formulation with rhodamine B (0.01%) were 
instilled into the rabbit eye. (One eye served as control and another eye 
as the test). The eyelids were held close for few second; the in situ gel so 
formed was visualized [22].
RESULTS AND DISCUSSION
Compatibility study of drug with different polymers  using FT-IR 
Spectrophotometer: FTIR spectra were measured using FTIR 
spectroscopy (8400S/Shimadzu Japan) to determine the possible 
interactions between drug and polymers. The pure drug, polymers, and 
drug-polymer physical mixture were scanned from 4000 to 400/cm in 
Shimadzu FTIR 8400S spectrophotometer using KBr pellet method. 
The IR spectrums of the physical mixture were compared with those 
of drug and polymers and matching was done to detect appearance or 
disappearance of peaks (Table 1).
23 Factorial design was employed to under the factors that are critical 
for the response. The main effect study and interaction study of factors 
reveals that concentration of the polymer plays as important role in 
viscosity, mucoadhesive study and percentage drug release in the 
development of formulation (Tables 2 and 3).
Polynomial equation coded factor
Gelation time (s)
As shown in the equation, the factors have a significant effect on the 
gelation time. The variables such as concentration of gelrite (A), 
xanthan gum (B), and HPMC E50 LV (C) have a negative effect on the 
gelation time. That means an increase in the concentration of GL, KC, 
and HP will show reduced gelation time. The higher concentration level 
of gelrite and xanthan gum gave the low value of gelation time at all 
level (Table 4).
Growth promoting organism Incubation 
temperature
Type Quantity of culture 
medium [17]
Quantity of test 
sample [18]
E. coli [15, 16] ATCC 8739 35°C Aerobic and anaerobic 10 ml 1 ml
Candida albicans ATCC 10231 25°C Fungi 10 ml 1 ml
E. coli: Escherichia coli
Table 1: Comparison of functional groups peaks wave no (cm−1) of BT samples testing by FTIR spectroscopy




Reported frequencies of drug in the physical 
mixtures BGXH*
N-H stretching 3500–3300 3400 3435
Aromatic C-H stretching 3100–3000 3000 2983
N-H bending 1640–1550 1593 1593
C=O stretching 1740–1690 1729 1731
-C=N- stretching 1680–1620 1652 1651
C=C stretching 1600–1400 1486 1486
C-O stretching 1300–1000 1300 1300
OH bending 1085–1050 1072 1073
C-Br stretching 600–500 583 600
BGXH*: Brimonidine tartrate with gelrite, xanthan gum and HPMC E50LV. BT: Brimonidine tartrate, FTIR: Fourier transform infrared, HPMC: Hydroxypropyl methyl 
cellulose
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Gel strength
As shown in the equation, the factors have a significant effect on the 
gel strength. The variables such as concentration of gelrite (A), xanthan 
gum (B), and HPMC E50 LV (C) have a positive effect on gel strength. 
That means an increase in the concentration of A, B, and C will show an 
increase in gel strength (Table 5).
Mucoadhesive force
As shown in the equation, the factors have a significant effect on the 
mucoadhesive force. The variables such as concentration of gelrite 
(A) xanthan gum (B) and HPMC E50 LV (C) have a positive effect on 
mucoadhesive force. That means an increase in the concentration of A, 
B, and C will show increase in mucoadhesive force (Table 6).
Viscosity before gel
As shown in the equation, the factors have a significant effect on the 
viscosity. The variables such as concentration of gelrite (A), xanthan 
gum (B), and HPMC E50 LV (C) have a have a positive effect on the 
viscosity. That means an increase in the concentration of A, B, and C will 
show increase viscosity (Table 7).
Cumulative drug release (%) 10th h: As shown in the equation, the 
factors have a significant effect on cumulative drug release. At 1st h 
the variables such as xanthan gum (B) and HPMC E50 LV (C) have a 
negative effect on drug release. Which means that B and C have drug 
release controlling capacity? Whereas A at 1st his not able control the 
drug release. Hence, A has shown a positive effect. AB and AC have 
shown a negative effect.
At 10th h, all polymers A, B, and C and their combination AB has shown the 
negative effect which indicates that increase in polymer concentration 
will reduce the percentage drug release. Which is significant for drug 
release? (Table 8).
Interaction studies of factors reveal that concentration of xanthan gum, 
gelrite, and HPMC E50 LV is critical factors. The concentration of xanthan 
gum should be carefully chosen to have proper mucoadhesive property. 
Desirability approach was utilized by setting a target to have a formulation 
which will have required properties of gelation time, gel strength, 
mucoadhesive property, viscosity, and in vitro drug release (Table 9).
These were further evaluated for the optimization responses (gelation 
time, gel strength, mucoadhesive force (N) viscosity (cP), and in vitro 
percentage drug release) to confirm the validity of optimization 
process, formulations exhibiting desirability like 0.903, close to 1 were 
selected as optimized formulation (Fig. 1).
The statistically optimized formulation fulfilled all the physicochemical 
criteria. The observed values were in close agreement with the model 
predictions. The relative errors (%) between the predicted and 
Table 2: Experimental layout of factors
Batch code Polymers (%)
Gelrite Xanthan gum HPMC E50
F1 0.4 0.4 0.2
F2 0.2 0.2 0.2
F3 0.4 0.4 0.4
F4 0.2 0.2 0.4
F5 0.2 0.4 0.4
F6 0.4 0.2 0.2
F7 0.4 0.2 0.4
F8 0.2 0.4 0.2
HPMC: Hydroxypropyl methyl cellulose
Table 3: Experimental layout of responses







(cP) at 50 
RPM±SD*
Cumulative % 
drug release at 1st  
h±SD*
Cumulative % 
drug release at 
10thh±SD*
F1 05±0.47 175±4.08 6.86±2.31 204±3.26 12.15±0.11 78.06±0.12
F2 11±0.94 020±1.63 4.18±3.25 043±1.24 20.57±0.39 95.32±0.64
F3 04±0.94 248±3.26 7.61±3.76 232±3.68 17.79±0.68 50.63±0.84
F4 09±1.88 035±2.05 4.05±1.71 055±2.16 24.50±0.68 61.19±0.72
F5 05±1.41 032±2.86 6.45±2.43 117±2.18 30.75±0.63 80.34±0.74
F6 07±0.47 042±2.44 4.48±3.30 046±2.44 40.79±0.82 95.67±0.56
F7 05±0.81 064±3.29 5.30±2.85 136±2.86 20.66±0.48 67.02±0.74
F8 09±0.81 045±3.08 4.35±3.97 090±1.69 25.56±0.57 83.72±0.76
*Standard deviation (n=3)
Table 4: ANOVA for response (gelation time)
ANOVA for selected factorial model
Partial sum of squares‑Type III Response: Gelation time (s)
Sourcemodel Sum of squares Df Mean square F value p>F
Model 125.17 7 17.88 10.47 0.0001 Significant
A-gelrite 60.17 1 60.17 35.22 0.0001 Significant
B-Xanthan G 24.00 1 24.00 14.05 0.0018 Significant
C-HPMC E50 32.67 1 32.67 19.12 0.0005 Not Significant
AB 2.67 1 2.67 1.56 0.2295 Not Significant
AC 2.67 1 2.67 1.56 0.2295 Not Significant
BC 1.50 1 1.50 0.88 0.3627 Not Significant
ABC 1.50 1 1.50 0.88 0.3627 Not significant
Pure error 27.33 16 1.71
Cor total 152.50 23
SD 1.31 R-squared 0.8208
Mean 6.75 Adj R-squared 0.7423
CV % 19.36 Pred R-squared 0.5967
PRESS 61.50 Adeq precision 9.276
Gelation time=6.75-1.58*A-1.00*B-1.17*C+0.33*A*B+0.33*A*C-0.25*B*C+0.25*A*B*C. HPMC: Hydroxypropyl methyl cellulose, CV: Curriculum vitae, SD: Standard 
deviation
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Table 5: ANOVA for response (gel strength)
ANOVA for selected factorial model
Partial sum of squares‑Type III Response: Gel strength (s)
Source model Sum of squares df Mean square F value p>F
Model 1.443E+005 7 20614.83 1446.65 0.0001 Significant
A-gelrite 59401.50 1 59401.50 4168.53 0.0001 Significant
B-Xanthan G 43010.67 1 43010.67 3018.29 0.0001 Significant
C-HPMC 3504.17 1 3504.17 245.91 0.0001 Significant
AB 32560.67 1 32560.67 2284.96 0.0001 Significant
AC 3313.50 1 3313.50 232.53 0.0001 Significant
BC 192.67 1 192.67 13.52 0.0020 Significant
ABC 2320.67 1 2320.67 162.85 0.0001 Significant
Pure error 228.00 16 14.25
Cor total 1.445E+005. 23
SD 3.77 R-squared 0.9984
Mean 82.58 Adj R-squared 0.9977
CV % 4.57 Pred R-squared 0.9965
PRESS 513.00 Adeq precision 104.614
Gel strength=82.58+49.75*A+42.33*B+12.08*C+36.83*AB+11.75*AC+2.83*BC+9.83*A*B*C. HPMC: Hydroxypropyl methyl cellulose, CV: Curriculum vitae, SD: Standard 
deviation
Table 6: ANOVA for response (mucoadhesive force)
ANOVA for selected factorial model
Partial sum of squares‑Type III Response: Mucoadhesive force (N)
Source model Sum of squares df Mean square F value p>F
Model 4197.20 599.60 19.26 0.0001 Significant
A-gelrite 329.82 7 329.82 10.59 0.0050 Significant
B-Xanthan G 0.77 1 0.77 0.025 0.0073 Significant
C-HPMC 487.89 1 487.89 15.67 0.0011 Significant
AB 1875.67 1 1875.67 60.24 0.0001 Significant
AC 291.14 1 291.14 9.35 0.0075 Significant
BC 966.09 1 966.09 31.03 0.0001 Significant
ABC 245.82 1 245.82 7.89 0.0126 Significant
Pure error 498.20 1 31.14
Cor total 4695.40 16
23
SD 5.58 R-squared 0.8939
Mean 55.25 Adj R-squared 0.8475
CV % 10.10 Pred R-squared 0.7613
PRESS 1120.95 Adeq precision 11.303
Mucoadhesive force=55.25+3.71*A+0.18*B+4.51*C+8.84*A*B-3.48*A*C-6.34*B*C+3.20*A*B*C. HPMC: Hydroxypropyl methyl cellulose, CV: Curriculum vitae, SD: 
Standard deviation
Table 7: ANOVA for response (viscosity before gel at 50 RPM): Batch No II
ANOVA for selected factorial model
Partial sum of squares‑Type III Response: Viscosity before gel at 50 RPM
Source model Sum of squares df Mean square F value p>F
Model 1.089E+005 7 15550.47 1588.13 <0.0001 Significant
A-gelrite 36895.04 1 36895.04 3768.00 <0.0001 Significant
B-xanthan gum 49232.04 1 49232.04 5027.95 <0.0001 Significant
C-HPMC 9322.04 1 9322.04 952.04 <0.0001 Significant
AB 7957.04 1 7957.04 812.63 <0.0001 Significant
AC 2380.04 1 2380.04 243.07 <0.0001 Significant
BC 805.04 1 805.04 82.22 <0.0001 Significant
ABC 2262.04 1 2262.04 231.02 <0.0001 Significant
Pure error 156.67 16 9.79
Cor total 1.090E+005 23
SD 03.13 R-squared 0.9986
Mean 115.46 Adj R-squared 0.9979
CV % 02.71 Pred R-squared 0.9968
PRESS 352.50 Adeq precision 104.615
Viscosity before gel=115.46+39.21*A+45.29*B+19.71*C+18.21*A*B+9.96*A*C-5.79*B*C-9.71*A*B*C. HPMC: Hydroxy propyl methyl cellulose, CV: Curriculum vitae, SD: 
Standard deviation
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Table 8: ANOVA for response (cumulative drug release (%) 10th h)
ANOVA for selected factorial model





df Mean square F value p>F
Model 5941.40 7 848.77 1232.99 <0.0001 Significant
A-gelrite 31.72 1 31.72 46.07 <0.0001 Significant
B-kappa Crgn 808.64 1 808.64 1174.68 <0.0001 Significant
C-HPMC E50 4838.51 1 4838.51 7028.76 <0.0001 Significant
AB 174.04 1 174.04 252.83 <0.0001 Significant
AC 0.76 1 0.76 1.10 0.3091 Not significant
BC 53.73 1 53.73 78.05 <0.0001 Significant
ABC 34.01 1 34.01 049.41 <0.0001 Significant
Pure error 11.01 16 0.69
Cor total 5952.42 23
SD 0.83 R-squared 0.9981
Mean 74.00 Adj R-squared 0.9973
CV % 01.12 Pred R-squared 0.9958
PRESS 24.78 Adeq precision 94.018
Cumulative drug release (%)=74-1.15*A-5.80*B-14.20*C-2.69*A*B+0.18*A*C+1.50*B*C-1.19*A*B*C. HPMC: Hydroxy propyl methyl cellulose, CV: Curriculum vitae, SD: 
Standard deviation
Table 9: Predicted and experimental observed responses of the optimized formulation with % prediction error











gel at 50 RPM




1 0.40 0.21 0.24 06.58 49.99 47.22 55.50 94.61 0.903
Observed value
2 0.40 0.21 0.24 06.86 51.94 46.31 55.20 92.45
% Predicted error
04.08 03.75 2.00 0.543 02.33
HPMC: Hydroxypropyl methyl cellulose
Fig. 1: Overlay graph of formulation optimization highlighting an area of operability
experimental values for each response were calculated, and the values 
found to be within 5%. The experimental values were in agreement 
with the predicted values, confirming the predictability and validity of 
the optimization process. In vitro release studies showed that HPMC 
E50 LV acts as release retardant. From the kinetic study, it was found 
the drug release from the optimized formulation followed first-order 
kinetics, since a straight line was obtained. From Higuchi plots, the plots 
were found to be linear which indicates the drug release from the in situ 
gel was by diffusion. The “n” values obtained from the Peppas equation 
were <0.5, which indicates the drug release by fickian diffusion 
mechanism.
The pH of formulations was within the range of comfort (6.8–7.8); 
hence, formulation will be tolerated by the eyes. Solutions showed 
less percentage transmittance because of the presence of polymers. 
Formed gels (mixing with STF (pH 7.4) showed greater percentage 
transmittance compared to solutions. Gels with optical transmission 
≥90% are termed as transparent, ≤90% but ≥10% as translucent, and 
≤10% as opaque. The study reveals that in situ gels were translucent. 
The sol-gel is dropped in the cul-de-sac where it forms a gel, the so 
formed gel will not spread over the eye (Table 10). Rheological studies 
manifested that the shear stress and viscosity at 37°C with STF were 
higher than those at 25°C without STF. It was noted from the various 
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literature that the solution before gelling should have a viscosity of 
5–1000 cPs and after gelling in the eye a viscosity from about 50 to 
50,000 cPs. The ocular shear rate is about 0.03/s during inter-blinking 
periods and 4250–28500/s during blinking. The viscosity of the 
solution ranged from 27 to 351 cps before gelation and 300 to 675 cP 
after gelation. Viscoelastic fluids having high viscosity under low shear 
rates and low viscosity under high shear rates, i.e., pseudo plastic fluid 
is often preferred. This may favor the sustained release of drug in the 
conjunctival sac of the eye and also without much blinking difficulty for 
shear thinning.
The formulation incubated with media suitable for the growth and 
proliferation of aerobic/anaerobic bacteria, fungi showed no growth 
at the end of 14 days at 35°C and at 25°C. No evidence of microbial 
growth/turbidity was found in the test and negative samples when 
compared with positive control media. This indicated that formulations 
were free from micro-organisms; which also proved the effectiveness 
of moist heat sterilization. Hence, the preparations being examined 
complies with the test for sterility (Table 10). Formulation showed no 
changes in size and shape of RBC (neither hypertonic nor hypotonic). 
This qualitative study showed that formulations are isotonic with blood 
(Table 10).
Formulations scoring were compared with those obtained using 
normal saline, 0.1N NaOH as controls. A means score of 0 was obtained 
for normal saline as well as for in situ gel-based formulation up to 5 min 
and no change was seen after 5 min also. The scoring for 0.1N NaOH 
found to be 15.00/10.20. The study shows that the formulation was non 
irritant, as results obtained by HET-CAM and those of the positive and 
negative controls (Figs. 2-4).
Ocular visualization showed that in situ gels were quickly formed when 
it comes in contact with the lachrymal fluid. Hence, it is easy to instill 
in the eye (Fig. 5).
CONCLUSION
An in situ gel-forming BT/xanthan gum eye drop using gellan gum as an 
ion-activated polymer was developed. The application of experimental 
design methodology helped to prepare the optimized formulation, 
which showed appropriate mucoadhesive force and in vitro percentage 
drug release. From the factorial design, the optimum concentrations 
of gelrite, HPMC E50 LV, and xanthan gum as mucoadhesive for the 
in situ ocular drug delivery system were 0.4%, 0.21%, and 0.24% 
(w/v), respectively. FTIR spectroscopy study reveals no significant 
interaction between drug and polymers. Hence, it is concluded that 
the drug to be compatible with polymers, ocular visualization showed 
optimized formulation showed evidence of phase transition and in situ 
gel structure formation on contact with cations of the STF. The in situ 
gel-formed was viscoelastic in nature and sustained the drug release 
for 10 h. The drug release from the in situ gel formed was by diffusion 
from the gel matrix. Formulation to be sterile ocular irritation studies 
showed the absence of hyperemia, hemorrhage, and coagulation. We 
can conclude that an optimized formulation was non irritant, as results 
obtained by HET-CAM and with those of the positive and negative 
controls. Ocular visualization showed optimized formulation showed 
evidence of phase transition and in situ gel structure formation on 
Table 10: Composite evaluation parameter of optimized 
formulation
S. No Evaluation parameters Optimized formulation
1 pH 7.46±0.094
2 Clarity (before gel) 44
3 Clarity (after gel) 84
4 Mucoadhesive force 46.50±3.48
5 Viscosity before gel at 50 RPM 192±04.89
6 In vitro drug release at 10th h 88.69±3.21
7 Isotonicity Isotonic
8 Ocular tolerance Non-irritant
9 Sterility test Sterile
10 Ocular visualization of in situ gels Easy to instill
*SD (n=3). SD: Standard deviation
Fig. 2: (a) Membrane with 0.1% NaoH at 0 min, (b) NaoH at 0.5 
min,(c) NaoH at 2 min, and (d) NaoH at 5 min
Fig. 3: (a) Membrane with 0.9% Nacl at 0 min, (b) Nacl at 0.5 min, 
(c) Nacl at 2 min, and (d) Nacl at 5 min
Fig. 3: (a) Membrane with 0.9% Nacl at 0 min, (b) Nacl at 0.5 min, 
(c) Nacl at 2 min, and (d) Nacl at 5 min
Fig. 5: (a) Normal rabbit left eye (LE) (b): Formulation F2 (colored 
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contact with cations of the STF. The effect of combining a mucoadhesive 
polymer to gelrite showed its ability to enhance bioavailability through 
its greater mucoadhesive strength which indicates longer precorneal 
residence time and also promises to reduce the frequency of drug 
administration, thus improving patient compliance.
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